Theriva Biologics shares are trading higher after the company announced it received a US patent application notice of allowance for treating C. Difficile disease and other antibiotic-induced GI tract adverse effects.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics shares rose following the announcement of a US patent application notice of allowance for a treatment targeting C. Difficile disease and other antibiotic-induced GI tract adverse effects.
August 28, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics' stock price increased after the company received a US patent application notice of allowance for a treatment for C. Difficile disease and other GI tract issues.
The notice of allowance for a US patent application is a significant milestone for Theriva Biologics, indicating potential future revenue from a new treatment. This positive development likely contributed to the rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100